{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:30:37Z","timestamp":1790101837997,"version":"4.0.1"},"reference-count":22,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006544","name":"Ministry of Health, State of Israel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2018,6,5]]},"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Retinopathy of prematurity (ROP) is a disease observed in extremely premature infants characterised by visioning-threatening retinal vessel proliferation. Propranolol, a drug used for decades in newborn infants with heart diseases, hypertension and thyrotoxicosis and licenced for infantile haemangiomas, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>ROPROP is an investigator-initiated, multicentre, placebo-controlled double-blind, randomised controlled trial aiming to assess the safety and efficacy of orally administered propranolol to reduce the risk of threshold ROP (stage 3) in extremely preterm infants at 48 weeks postmenstrual age (primary objective) and the rate of infants requiring local interventions for severe ROP (secondary objective). Key inclusion criteria: gestational age &lt;28 weeks, birth weight &lt;1250\u2009g, postmenstrual age \u226531\u2009and &lt;37 weeks, incipient ROP (stage 1 or 2, with or without plus disease) and written informed consent by parents or legal guardian. Key exclusion criteria: requirement for open-label propranolol treatment, major congenital malformations (including those with cerebrovascular malformations), known chromosomal anomalies, colobomas and other eye malformations, atrioventricular block grade 2 or 3 and comedication with antiarrhythmics, clonidine, insulin (pharmacodynamic interaction), phenobarbital or rifampicin (pharmacokinetic interaction). The intervention consists of oral propranolol-hydrochloride (1.6\u2009mg\/kg\/day in three to four divided dosages) or placebo until discharge, for a maximum of 10 weeks. Analysis is by intention to treat.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol has received ethical and regulatory approval. Results will be published after peer review irrespective of the study outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration numbers<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"NCT03083431\" ext-link-type=\"clintrialgov\" specific-use=\"clinicaltrial pre-results\">NCT03083431<\/jats:ext-link>\n                      , EudraCT# 2017\u2010002124\u201024 (EUCTR), 00013730 (DRKS); Pre-results.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2018-021749","type":"journal-article","created":{"date-parts":[[2018,7,7]],"date-time":"2018-07-07T03:00:55Z","timestamp":1530932455000},"page":"e021749","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct03083431","registry":"10.18810\/clinical-trials-gov","type":"preResults"},{"clinical-trial-number":"nct01238471","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02504944","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Christoph","family":"B\u00fchrer","sequence":"first","affiliation":[{"name":"Department of Neonatology, Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6mer","family":"Erdeve","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Ankara University School of Medicine Children\u2019s Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Bassler","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Universit\u00e4tsspital Z\u00fcrich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bar-Oz","sequence":"additional","affiliation":[{"name":"Department of Neonatology, Hadassah Medical Center, Jerusalem, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,7,6]]},"reference":[{"key":"2025121407361424000_8.7.e021749.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(64)91275-9"},{"key":"2025121407361424000_8.7.e021749.2","unstructured":"WHO. WHO expert committee on selection and use of essential medicines. WHO model list of essential medicines for children (6th edition). 2017 http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/6th_EMLc2017.pdf2017"},{"key":"2025121407361424000_8.7.e021749.3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-0377"},{"key":"2025121407361424000_8.7.e021749.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2015.07.067"},{"key":"2025121407361424000_8.7.e021749.5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-0806"},{"key":"2025121407361424000_8.7.e021749.6","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308375"},{"key":"2025121407361424000_8.7.e021749.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1007374"},{"key":"2025121407361424000_8.7.e021749.8","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1001\/jamaophthalmol.2014.2772","article-title":"Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial","volume":"132","author":"Geloneck","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"2025121407361424000_8.7.e021749.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2011.07530.x"},{"key":"2025121407361424000_8.7.e021749.10","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5536"},{"key":"2025121407361424000_8.7.e021749.11","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9691"},{"key":"2025121407361424000_8.7.e021749.12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/jpm-2015-0357","article-title":"Oral propranolol in early stages of retinopathy of prematurity","volume":"44","author":"Bancalari","year":"2016","journal-title":"J Perinat Med"},{"key":"2025121407361424000_8.7.e021749.13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3109\/02713683.2016.1158272","article-title":"The efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index","volume":"42","author":"Korkmaz","year":"2017","journal-title":"Curr Eye Res"},{"key":"2025121407361424000_8.7.e021749.14","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303951"},{"key":"2025121407361424000_8.7.e021749.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.07.049"},{"key":"2025121407361424000_8.7.e021749.16","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2016-311548"},{"key":"2025121407361424000_8.7.e021749.17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000381659","article-title":"Oral propranolol: a new treatment for infants with retinopathy of prematurity?","volume":"108","author":"B\u00fchrer","year":"2015","journal-title":"Neonatology"},{"key":"2025121407361424000_8.7.e021749.18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/pr.2016.230","article-title":"Propranolol 0.1% eye micro-drops in newborns with retinopathy of prematurity: a pilot clinical trial","volume":"81","author":"Filippi","year":"2017","journal-title":"Pediatr Res"},{"key":"2025121407361424000_8.7.e021749.19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12887-017-0923-8","article-title":"Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial","volume":"17","author":"Filippi","year":"2017","journal-title":"BMC Pediatr"},{"key":"2025121407361424000_8.7.e021749.20","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"2025121407361424000_8.7.e021749.21","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/pr.2017.179","article-title":"N-terminal B-type natriuretic peptide urinary concentrations and retinopathy of prematurity","volume":"82","author":"B\u00fchrer","year":"2017","journal-title":"Pediatr Res"},{"key":"2025121407361424000_8.7.e021749.22","doi-asserted-by":"publisher","DOI":"10.3758\/BRM.41.4.1149"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2018-021749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:36:25Z","timestamp":1765726585000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2018-021749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,6]]},"published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1136\/bmjopen-2018-021749"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2018-021749","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}